Dyadic International To Present At Two Major Conferences In December 2013
JUPITER, Fla., Nov. 21, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI) ("Dyadic" or "the Company"), a global leader in the commercial application of biotechnology for the discovery, development and production of enzymes and other proteins, today announced that the Company will present at the following conferences:
- The LD Micro "Main Event" Conference, a premier small-cap conference to be held December 3-5, 2013 at the Luxe Hotel in Los Angeles, California. On Wednesday, December 4, 2013, Dyadic Chairman and Chief Executive Officer Mark Emalfarb will present in Track Three at 10:00 a.m. PST. Mr. Emalfarb will be available for individual meetings throughout the conference. For registration information, please visit the conference website at http://www.ldmicro.com.
- Biotechnology Industry Organization's 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy, to be held December 8-11, 2013 at the Westin Gaslamp Quarter in San Diego, California. On Monday, December 9, 2013, Dyadic Chief Operating Officer Danai Brooks will present at the "Development of New Industrial Enzymes" panel at Track 5 "Technical and Research Presentations" at 8:30-10:00 a.m. PST. Mr. Brooks will be available for individual meetings throughout the conference. For registration information, please visit the conference website at http://www.bio.org/events.
To schedule a meeting with the Company, please contact its outside investor relations firm ICR at the number below.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
SOURCE Dyadic International, Inc.